All these findings suggest that resmetirom might improve NAFLD/NASH by influencing the activation of the Toll-like receptor and Jak-STAT3 signaling pathways, as both of them have been proven to take part in regulating inflammation and contribute to the development of NASH [22,23]. Here, STAT3 is linked to metabolic dysfunction-associated steatotic liver disease.